335 related articles for article (PubMed ID: 33613180)
1. Advances of Mechanisms-Related Metabolomics in Parkinson's Disease.
Zhang Y; Li J; Zhang X; Song D; Tian T
Front Neurosci; 2021; 15():614251. PubMed ID: 33613180
[TBL] [Abstract][Full Text] [Related]
2. Current perspective of mitochondrial biology in Parkinson's disease.
Ammal Kaidery N; Thomas B
Neurochem Int; 2018 Jul; 117():91-113. PubMed ID: 29550604
[TBL] [Abstract][Full Text] [Related]
3. NMR Metabolomics Analysis of Parkinson's Disease.
Lei S; Powers R
Curr Metabolomics; 2013; 1(3):191-209. PubMed ID: 26078917
[TBL] [Abstract][Full Text] [Related]
4. Exploring the interplay between metabolomics and genetics in Parkinson's disease: Insights from ongoing research and future avenues.
Santos-Rebouças CB; Cordovil Cotrin J; Dos Santos Junior GC
Mech Ageing Dev; 2023 Dec; 216():111875. PubMed ID: 37748695
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial dysfunctions in Parkinson's disease.
Gautier CA; Corti O; Brice A
Rev Neurol (Paris); 2014 May; 170(5):339-43. PubMed ID: 24119854
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of nigral cell death in Parkinson's disease.
Przedborski S
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial Dysfunction in Parkinson's Disease: New Mechanistic Insights and Therapeutic Perspectives.
Park JS; Davis RL; Sue CM
Curr Neurol Neurosci Rep; 2018 Apr; 18(5):21. PubMed ID: 29616350
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial dysfunction in Parkinson's disease.
Hu Q; Wang G
Transl Neurodegener; 2016; 5():14. PubMed ID: 27453777
[TBL] [Abstract][Full Text] [Related]
9. Emerging concepts of mitochondrial dysfunction in Parkinson's disease progression: Pathogenic and therapeutic implications.
Rani L; Mondal AC
Mitochondrion; 2020 Jan; 50():25-34. PubMed ID: 31654753
[TBL] [Abstract][Full Text] [Related]
10. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
11. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial remodeling in human skin fibroblasts from sporadic male Parkinson's disease patients uncovers metabolic and mitochondrial bioenergetic defects.
Deus CM; Pereira SP; Cunha-Oliveira T; Pereira FB; Raimundo N; Oliveira PJ
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165615. PubMed ID: 31759069
[TBL] [Abstract][Full Text] [Related]
13. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
Hattori N
Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
[TBL] [Abstract][Full Text] [Related]
14. Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease.
Shao Y; Le W
Mol Neurodegener; 2019 Jan; 14(1):3. PubMed ID: 30634989
[TBL] [Abstract][Full Text] [Related]
15. Dopamine, Alpha-Synuclein, and Mitochondrial Dysfunctions in Parkinsonian Eyes.
Indrieri A; Pizzarelli R; Franco B; De Leonibus E
Front Neurosci; 2020; 14():567129. PubMed ID: 33192254
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
Mandel S; Grunblatt E; Riederer P; Amariglio N; Jacob-Hirsch J; Rechavi G; Youdim MB
Ann N Y Acad Sci; 2005 Aug; 1053():356-75. PubMed ID: 16179542
[TBL] [Abstract][Full Text] [Related]
17. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
Duda J; Pötschke C; Liss B
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin phosphorylation in Parkinson's disease: Implications for pathogenesis and treatment.
Chin LS; Li L
Transl Neurodegener; 2016; 5():1. PubMed ID: 26740872
[TBL] [Abstract][Full Text] [Related]
19. Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism.
Asanuma M; Miyazaki I; Diaz-Corrales FJ; Ogawa N
Acta Med Okayama; 2004 Oct; 58(5):221-33. PubMed ID: 15666991
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers in Parkinson's disease (recent update).
Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
